FBR & Co Weighs in on Supernus Pharmaceuticals, Inc.’s Q3 2017 Earnings (SUPN)

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – Equities research analysts at FBR & Co issued their Q3 2017 EPS estimates for Supernus Pharmaceuticals in a research note issued on Wednesday. FBR & Co analyst D. Buck anticipates that the specialty pharmaceutical company will earn $0.28 per share for the quarter. FBR & Co has a “Buy” rating and a $53.00 price objective on the stock. FBR & Co also issued estimates for Supernus Pharmaceuticals’ Q4 2017 earnings at $0.25 EPS, FY2017 earnings at $1.05 EPS, Q1 2018 earnings at $0.27 EPS, Q2 2018 earnings at $0.42 EPS, Q3 2018 earnings at $0.48 EPS, Q4 2018 earnings at $0.53 EPS and FY2018 earnings at $1.70 EPS.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.08. The firm had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%.

TRADEMARK VIOLATION NOTICE: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://www.com-unik.info/2017/10/22/fbr-co-weighs-in-on-supernus-pharmaceuticals-inc-s-q3-2017-earnings-supn.html.

Several other equities research analysts also recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating and set a $49.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 27th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $41.00 target price on shares of Supernus Pharmaceuticals in a report on Tuesday, September 26th. Cowen and Company reaffirmed a “buy” rating and set a $50.00 target price on shares of Supernus Pharmaceuticals in a report on Thursday, September 21st. Jefferies Group LLC reaffirmed a “buy” rating and set a $51.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Finally, Janney Montgomery Scott reaffirmed a “hold” rating and set a $47.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $48.38.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at 41.85 on Friday. The stock has a market cap of $2.12 billion, a PE ratio of 21.12 and a beta of 1.30. The company’s 50-day moving average price is $42.84 and its 200-day moving average price is $39.71. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $50.05.

A number of large investors have recently bought and sold shares of the stock. Pinebridge Investments L.P. raised its position in Supernus Pharmaceuticals by 1.3% during the second quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock valued at $285,000 after buying an additional 86 shares during the period. Louisiana State Employees Retirement System raised its position in Supernus Pharmaceuticals by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock valued at $884,000 after buying an additional 100 shares during the period. Arizona State Retirement System raised its position in Supernus Pharmaceuticals by 0.4% during the second quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company raised its position in Supernus Pharmaceuticals by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock valued at $1,579,000 after buying an additional 128 shares during the period. Finally, CS Mckee LP raised its position in Supernus Pharmaceuticals by 0.5% during the second quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock valued at $1,812,000 after buying an additional 200 shares during the period. 95.36% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction on Friday, September 8th. The stock was sold at an average price of $47.60, for a total transaction of $2,380,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the company’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $49.86, for a total value of $249,300.00. Following the transaction, the senior vice president now directly owns 12,500 shares in the company, valued at $623,250. The disclosure for this sale can be found here. Insiders have sold 153,709 shares of company stock worth $7,223,108 over the last three months. 6.70% of the stock is owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit